Study S002765

A Double-blind, Randomized, Placebo-controlled, Sequential, Single, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of Subcutaneous Injections of GZR18 in Healthy Subjects

ClinicalTrials.gov record

Registration

Registration: NCT05328726
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 24
Start: 2022-03-08
Primary completion: 2023-02-09
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:GZR-18; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

Dose limiting toxicity [Up to 31 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.